Last HV Out！Leadingtac Announces Completion of All Healthy Volunteers Dosed in Phase I Clinical Trial of First Pipeline IRAK4 Degrader-Shanghai Leadingtac Pharmaceutical Co., Ltd.

News

Strive forward with partners and pursue dreams

Last HV Out！Leadingtac Announces Completion of All Healthy Volunteers Dosed in Phase I Clinical Trial of First Pipeline IRAK4 Degrader

Last HV Out！Leadingtac Announces Completion of All Healthy Volunteers Dosed in Phase I Clinical Trial of First Pipeline IRAK4 Degrader

Great news in the New Year! Leadingtac won the “2024 Jin Kai High-Quality Entrepreneurship Award” in Keqiao Economic Development Zone!

Leadingtac Secures Over $14 million Series A Financing secures for IRAK4 degraders

Big congratulations to Dr. Zhengqing Ye of Leadingtac was awarded with one of the “Pearl Elite Talent” in Pudong New Area in 2024

Return

Last HV Out！Leadingtac Announces Completion of All Healthy Volunteers Dosed in Phase I Clinical Trial of First Pipeline IRAK4 Degrader

2025-05-17

Prev：Last HV Out！Leadingtac Announces Completion of All Healthy Volunteers Dosed in Phase I Clinical Trial of First Pipeline IRAK4 Degrader

Next：Great news in the New Year! Leadingtac won the “2024 Jin Kai High-Quality Entrepreneurship Award” in Keqiao Economic Development Zone!

Blaze a new path in the development of targeted protein degradation drugs.

Since 2019

Major Milestones

Management Team

Industry Information

Employment Philosophy

Development Space

Room 501, 781 Cailun Road, Pilot Free Trade Zone, Pudong, Shanghai, China

+86-(0)21-50561622

hr@leadingtac.com/yxie@leadingtac.com

Company Mailbox

hr@leadingtac.com
yxie@leadingtac.com

Official Account

Copyright © 2025 Shanghai Leadingtac Pharmaceutical Co., Ltd. All Rights Reserved. 沪ICP备2022020812号-1

Design by jijin